Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E18.63 EPS (ttm)3.49 Insider Own0.10% Shs Outstand1.63B Perf Week2.70%
Market Cap105.82B Forward P/E11.48 EPS next Y5.66 Insider Trans-27.40% Shs Float1.63B Perf Month-0.12%
Income5.72B PEG1.15 EPS next Q1.20 Inst Own71.80% Short Float2.40% Perf Quarter9.51%
Sales24.75B P/S4.27 EPS this Y185.20% Inst Trans1.89% Short Ratio5.47 Perf Half Y17.95%
Book/sh3.47 P/B18.73 EPS next Y17.71% ROA10.00% Target Price71.28 Perf Year19.31%
Cash/sh4.91 P/C13.22 EPS next 5Y16.25% ROE119.80% 52W Range44.16 - 68.12 Perf YTD12.89%
Dividend2.28 P/FCF25.82 EPS past 5Y3.50% ROI16.90% 52W High-5.52% Beta1.50
Dividend %3.51% Quick Ratio1.60 Sales past 5Y7.90% Gross Margin78.60% 52W Low45.74% ATR0.95
Employees28000 Current Ratio1.80 Sales Q/Q17.80% Oper. Margin35.00% RSI (14)50.68 Volatility1.39% 1.38%
OptionableYes Debt/Eq6.71 EPS Q/Q17.90% Profit Margin23.10% Rel Volume0.63 Prev Close64.98
ShortableYes LT Debt/Eq6.62 EarningsOct 28 BMO Payout63.30% Avg Volume7.14M Price64.36
Recom2.30 SMA200.54% SMA50-1.00% SMA2008.12% Volume1,359,247 Change-0.95%
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Sep-26-16 11:04AM  Whats the Upside Potential for Gilead?
10:10AM  Stock Market News for September 26, 2016
09:00AM  AbbVie Showcases Commitment to Research and Innovation in Dermatology at the 25th European Academy of Dermatology and Venereology Congress PR Newswire
08:52AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : September 26, 2016
08:46AM  AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb
08:35AM  Jefferies Makes Huge New Stock Addition to Franchise Picks List at 24/7 Wall St.
07:00AM  AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma PR Newswire
06:49AM  Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval
Sep-23-16 07:42PM  FDA Approves Amgen's Biosimilar Version of Humira at The Wall Street Journal
06:22PM  FDA approves lower-cost alternative to biotech drug Humira
05:50PM  U.S. FDA approves Amgen's copy of AbbVie arthritis drug Humira Reuters
04:44PM  U.S. FDA approves Amgen's cheaper copy of arthritis drug Humira
01:04PM  Why Analysts Expect Gileads Revenue to Fall in 2016 and 2017
06:05AM  3 Dividend Investing Tips That Could Earn You Thousands at Motley Fool
04:00AM  AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C PR Newswire
Sep-22-16 06:32PM  3 Top Dividend Stocks for Your Roth IRA at Motley Fool
03:00PM  AbbVie Is Gaining Traction -- Here's How to Trade It From Here
10:48AM  The Pros and Cons of Buying Gilead Sciences Stock at Motley Fool
Sep-21-16 01:00PM  Trend Channel Buying Opportunity in These Stocks (ABBV, RTN) at Investopedia
07:30AM  [$$] Thiel Backs Biotech Anew as Compass Therapeutics Gets $50M at The Wall Street Journal
Sep-20-16 05:25PM  Apple, General Electric, Microsoft Top Q2 In Stock Buybacks
05:20PM  AbbVie Joins BioArctic in Fight Against Parkinson's Disease
02:32PM  AbbVie (ABBV) Stock Gains on BioArctic Parkinson's Collaboration
08:20AM  4 Jefferies Large Cap Franchise Picks That Also Pay Solid Dividends at 24/7 Wall St.
03:48AM  Karolinska Development portfolio company BioArctic enters into Collaboration with AbbVie for Parkinson's Disease Research GlobeNewswire
Sep-19-16 04:04PM  How Valeant Plans to Its Fix Dermatology Portfolio
08:36AM  BTIG Downgrades OraSure Technologies To Neutral Citing Valuation
Sep-16-16 12:49PM  Vertex: Did Management Deliver Investors a Backhanded Slap? at
08:50AM  The Top 10 S&P 500 Dividend Stocks to Buy Now at Kiplinger
Sep-15-16 03:00PM  The Cannabis-Based Biotech Sector's Best Buyout Candidates at Forbes
09:13AM  Better Buy: Pfizer Inc. vs. AbbVie Inc. at Motley Fool
07:30AM  New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA (Daclizumab) and Support Long-Term Safety Profile Business Wire
Sep-14-16 06:46PM  [$$] Delinia Raises $35M Series A for Autoimmune Drug Development at The Wall Street Journal
08:17AM  AbbVie's Battle Royale
07:00AM  Our Ultimate Stock-Pickers Top 10 Dividend-Yielding Stocks at Morningstar
Sep-13-16 01:32PM  Why Gilead Sciences Loves PARPAnd You Should Too at
01:20PM  Big Pharma Spends Millions to Keep Prices High for California Agencies
10:25AM  Jefferies Issues Top Pharma and Biohealth Stocks to Buy at 24/7 Wall St.
09:30AM  The Zacks Analyst Blog Highlights: Spectrum Pharmaceuticals, Amgen, AbbVie and Vertex Pharmaceuticals
08:04AM  Product Launches Are Part of Biogens Plans to Boost Revenues
07:25AM  Major Pharma Continues to See Significant Drop in Short Interest at 24/7 Wall St.
12:06AM  [$$] High Cost of New Hepatitis C Drugs Strains Prison Budgets, Locks Many Out of Cure at The Wall Street Journal
Sep-12-16 09:23AM  3 Drug Stocks That Could Benefit from Key FDA Events in Sep 2016
Sep-09-16 11:53AM  AbbVie Declares Quarterly Dividend PR Newswire
11:04AM  Analysts Look for Celgene to Offer Striking Returns in 2016
Sep-08-16 04:04PM  Lilly Upgraded On Pipeline Prospects; AbbVie Downgraded
01:23PM  Better Buy: Biogen Inc. vs. Gilead Sciences at Motley Fool
10:42AM  AbbVie (ABBV) Stock Retreats, JPMorgan Downgrades
09:59AM  JPMorgan: AbbVie's Gone as High as It's Gonna Go at
08:15AM  Analysts' Actions -- Apple, Lululemon, Nike, Tractor Supply and More
06:02AM  AbbVie downgraded by JP Morgan
Sep-07-16 04:13PM  Goldman's 7 Favorite Biotech Ideas For 2016
02:04PM  Celgenes Enterprise Value to Earnings in Line with Peers
11:41AM  Understanding Celgenes Premium PE Valuation
10:42AM  Abbvie Is One Of The Most 'Dislocated Names' In Pharma
09:45AM  Drug prices are back in the spotlight here are the companies with the most to lose
Sep-06-16 05:58PM  AbbVie: Investors Apprehensive About Humira
11:48AM  8 Stocks for a Health Care Revival at
08:58AM  [$$] Health-Care Returns Outpace Tech as Advances Reshape Industry at The Wall Street Journal
08:06AM  Gilead Sciences Inc.'s 5 Best Moves in 2016 So Far at Motley Fool
08:04AM  VeriFone (PAY), Genesco (GCO): Analysts Slashed Their Price Targets On These 5 Stocks Last Week at Insider Monkey
Sep-05-16 08:04AM  Why Pfizers Enbrel Faces a Sales Decline
Sep-02-16 03:08PM  AbbVie: Not Your Father's Biotech Company? at
02:30PM  Street Talk: Abbvie, Lululemon & more
12:30PM  Raymond James: Abbvie has value-enhancing catalysts
10:11AM  10 Conditions That Could Soon Be Treated With Cannabis: From Menstrual Cramps To Autism
07:20AM  3 Stocks to Add to Your Social Security Benefits at Motley Fool
Sep-01-16 06:03PM  2 Biotech Biosimilar Winners at
Aug-31-16 08:50AM  7 Healthy Dividend Stocks for Quality and Security at Kiplinger
08:15AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : August 31, 2016
Aug-30-16 08:00AM  AbbVie to Present at the Morgan Stanley Global Healthcare Conference PR Newswire
Aug-29-16 09:49AM  Better Buy: GlaxoSmithKline plc vs. AbbVie at Motley Fool
Aug-27-16 12:01AM  [$$] The 10 Best Dividend Stocks at
Aug-26-16 03:57PM  AbbVie Inc (ABBV) Expected To Launch Zinbryta In The US This Month at Insider Monkey
10:04AM  AbbVie Expects Investigational Drug Elagolix to Be a Blockbuster
08:04AM  Could Zinbryta Become a Novel Immunomodulatory Therapy for MS?
Aug-25-16 11:04AM  AbbVie Launched Zinbryta in the US in August
10:04AM  How Late-Stage Asset Rova-T Could Become a Leading Therapy
08:45AM  Major Pharma Short Interest Faces Significant Drop at 24/7 Wall St.
08:04AM  How AbbVie Expects BCL-2 Inhibitor Venclexta to Prove Effective
Aug-24-16 12:10PM  Why OraSure Technologies, Inc is Jumping Today at Motley Fool
11:04AM  Litigation Has Teva Pharmaceuticals Copaxone 40 mg All Tied Up
11:04AM  Imbruvica Continues to Report Better-than-Expected Sales in 2016
10:04AM  How Humira-Related Uncertainty Has Affected AbbVies Valuations
08:04AM  AbbVie Expects to Commercialize Selective JAK1 Inhibitor ABT-494
Aug-23-16 03:04PM  How AbbVie Expects Risankizumab to Be a Transformative Therapy
02:04PM  What Are Analysts Recommendations for AbbVie in 2016?
11:47AM  How AbbVies Valuation Multiples Compare with Its Peers
12:09AM  [$$] Pfizers Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
Aug-22-16 01:24PM  [$$] Pfizer makes $14bn bet on cancer drugmaker Medivation at Financial Times
12:22PM  [$$] Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
09:05AM  Can Allergan Generics Boost Teva Pharmaceuticals 2016 Revenues?
08:22AM  Johnson & Johnson Could Become the First Company to Reach a $1 Trillion Valuation at Motley Fool
07:20AM  [$$] Pfizer agrees $14bn takeover of Medivation at Financial Times
Aug-21-16 08:02PM  Harvard Explains The Health Effects Of Medical And Recreational Use Of Marijuana
06:45AM  Here's the Best Dividend Stock in Big Pharma at Motley Fool
Aug-19-16 09:30AM  Zacks Value Investor Highlights: AbbVie, Berry Plastics, Hawaiian Holdings, Toll Brothers and Pulte
08:08AM  3 Cheap Dividend Stocks You Can Buy Right Now at Motley Fool
07:00AM  No Pain, Potential for Lots of Gain at Morningstar
Aug-18-16 04:21PM  10 Highest Healthcare Dividend Stocks at Motley Fool
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; and Alvine Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schumacher Laura JExecutive Vice PresidentSep 07Sale65.0050,0003,250,000144,138Sep 09 05:38 PM
Schumacher Laura JExecutive Vice PresidentJun 24Option Exercise27.62186,1065,140,971380,244Jun 28 05:47 PM
Schumacher Laura JExecutive Vice PresidentJun 24Sale60.03186,10611,171,173194,138Jun 28 05:47 PM
GONZALEZ RICHARD AChairman of the Board and CEOJun 02Sale63.82285,95318,249,712338,421Jun 03 05:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 11Sale63.8039,0002,488,200338,421May 13 05:11 PM
HURWICH THOMAS A.VP, ControllerMay 10Option Exercise27.296,000163,74068,204May 12 05:44 PM
HURWICH THOMAS A.VP, ControllerMay 10Sale63.596,000381,54162,204May 12 05:44 PM
ALBAN CARLOSEVP, Commercial OperationsMay 10Sale63.5247,4383,013,262149,444May 12 05:39 PM
Schumacher Laura JExecutive Vice PresidentMar 08Sale56.0925,0001,402,341194,138Mar 08 05:23 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Option Exercise22.943,40077,9985,143Feb 09 05:13 PM